AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29349999 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of Diprospan, Lidocaine, and Mecobalamine after PELD
Number of subjects: 126
Study 29349999 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection after PELD
Number of subjects: 126
Study 29349999 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PELD with and without epidural injection)
Number of subjects: 126
Study 25241958 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Re‐Know intervention (e-feedback knowledge of radiotherapy)
Number of subjects: 126
Study 25241958 — intervention group
Group type: COMPARATOR
Intervention: Standard education (control group)
Number of subjects: 126
Study 23702610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed valve implant surgery with combined short scleral tunnel with Tenon advancement and duplication technique
Number of subjects: 276
Study 23702610 — intervention group
Group type: COMPARATOR
Intervention: AGV implant surgery without patch graft
Number of subjects: 276
Study 23702610 — intervention group
Group type: COMPARATOR
Intervention: AGV implant surgery with donor scleral patch
Number of subjects: 276
Study 21388309 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg once daily)
Number of subjects: 4447
Study 21388309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4447
Study 21388309 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 4447
Study 19930508 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated testing (SE-T/MG-S group)
Number of subjects: 40
Study 19930508 — intervention group
Group type: COMPARATOR
Intervention: Repeated study (MG-T/SE-S group)
Number of subjects: 40
Study 16368389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Surgery (LVRS)
Number of subjects: 62
Study 16368389 — intervention group
Group type: COMPARATOR
Intervention: Best Medical Care (BMC)
Number of subjects: 62
Study 15320662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute rest interval
Number of subjects: 30
Study 15320662 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute rest interval
Number of subjects: 30
Study 15320662 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute rest interval
Number of subjects: 30
Study 15320662 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 11298707 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 nm scanning diode laser at 48 J/cm2
Number of subjects: 36
Study 11298707 — intervention group
Group type: COMPARATOR
Intervention: 800 nm scanning diode laser at 24, 38, or 48 J/cm2
Number of subjects: 36
Study 9260068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5, 1.0, and 2.0 g/kg)
Number of subjects: 8
Study 9260068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital (150, 300, 600, and 750 mg/70 kg)
Number of subjects: 8
Study 9260068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7644443 — intervention group
Group type: EXPERIMENTAL
Intervention: Predisposing factors (beliefs, perceived benefits, and motivation)
Number of subjects: 16287
Study 7644443 — intervention group
Group type: COMPARATOR
Intervention: Enabling factors (barriers, norms, and social support)
Number of subjects: 16287
Study 2501383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dextroamphetamine 20 mg
Number of subjects: 24
Study 2501383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 81190 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (BACON combination, slightly modified)
Number of subjects: 32
Study 81190 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (adriamycin plus cyclophosphamide)
Number of subjects: 32
Study 81190 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen CVP (cyclophosphamide plus vincristine plus prednisone)
Number of subjects: 32
Study 81190 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 32
Study 28452960 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg per day Pycnogenol® (P+)
Number of subjects: 33
Study 28452960 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Co)
Number of subjects: 33
Study 26035682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsiflexed (DF) position stretching
Number of subjects: 34
Study 26035682 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar-flexed (PF) position stretching
Number of subjects: 34
Study 26035682 — intervention group
Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 34
Study 24306695 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/mL rhBMP-2/CPM
Number of subjects: 369
Study 24306695 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/mL rhBMP-2/CPM
Number of subjects: 369
Study 24306695 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffer/CPM
Number of subjects: 369
Study 24306695 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 369
Study 21880996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical stimulation
Number of subjects: 60
Study 19836626 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA (400mg/day)
Number of subjects: 14
Study 17099012 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (oral hypnotic agent)
Number of subjects: 72
Study 17099012 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 72
Study 17099012 — intervention group
Group type: COMPARATOR
Intervention: Standard care (neither zolpidem nor placebo)
Number of subjects: 72
Study 17099012 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Zolpidem, Placebo, Standard Care)
Number of subjects: 72
Study 15640625 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions from a standardized patient to military healthcare providers
Number of subjects: 0
Study 15640625 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11720425 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU plus levamisole
Number of subjects: 1029
Study 11720425 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further treatment)
Number of subjects: 1029
Study 8907804 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen [200 mg orally twice daily (p.o. b.i.d.) for a week]
Number of subjects: 30
Study 8907804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1685875 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lormetazepam alone
Number of subjects: 10
Study 1685875 — intervention group
Group type: COMPARATOR
Intervention: 1 mg lormetazepam with 200 mg cimetidine
Number of subjects: 10
Study 6416513 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 103
Study 6416513 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 103
Study 6416513 — intervention group
Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 103
Study 31266826 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) diet high in whole grains, legumes, fruits, and vegetables (WG)
Number of subjects: 80
Study 31266826 — intervention group
Group type: COMPARATOR
Intervention: High glycemic load (GL) diet high in refined grains and added sugars (RG)
Number of subjects: 80
Study 28465460 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA + stentriever thrombectomy
Number of subjects: 173
Study 28465460 — intervention group
Group type: COMPARATOR
Intervention: tPA alone
Number of subjects: 173
Study 25402429 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% M. hamburg grape seed extract formulation
Number of subjects: 0
Study 25402429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (base)
Number of subjects: 0
Study 25037002 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic group (TG) rehabilitation interventions
Number of subjects: 165
Study 25037002 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 165
Study 25037002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TG and CG)
Number of subjects: 165
Study 22658389 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G FNA
Number of subjects: 56
Study 22658389 — intervention group
Group type: COMPARATOR
Intervention: 22G FNB
Number of subjects: 56
Study 19734628 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR (O‐LAR)
Number of subjects: 7
Study 19734628 — intervention group
Group type: COMPARATOR
Intervention: Octreotide short‐acting (O‐SA)
Number of subjects: 7
Study 17634482 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2171 (0.5 to 60 mg, once-daily)
Number of subjects: 83
Study 17634482 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2171 (20, 30, or 45 mg, once-daily)
Number of subjects: 83
Study 17634482 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2171 (once-daily)
Number of subjects: 83
Study 15459209 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline health‐related quality of life (HRQOL) parameters assessed by the EORTC QLQ‐C30
Number of subjects: 391
Study 15459209 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including HRQOL factors
Number of subjects: 391
Study 15459209 — intervention group
Group type: COMPARATOR
Intervention: Model without HRQOL factors
Number of subjects: 391
Study 12397471 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain perfusion SPET with PVE correction
Number of subjects: 30
Study 12397471 — intervention group
Group type: COMPARATOR
Intervention: Brain perfusion SPET without PVE correction
Number of subjects: 30
Study 9817092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound detection of renal scarring
Number of subjects: 339
Study 9817092 — intervention group
Group type: COMPARATOR
Intervention: DMSA scintigraphy
Number of subjects: 339
Study 7535040 — intervention group
Group type: COMPARATOR
Intervention: Single-donor plateletpheresis concentrates (Group A)
Number of subjects: 40
Study 7535040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (6 x 10(6) KIU) (Group B)
Number of subjects: 40
Study 14589683 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending to the signal while shadowing the story (Experiment 1)
Number of subjects: 48
Study 14589683 — intervention group
Group type: EXPERIMENTAL
Intervention: Did not shadow the story (Experiment 2)
Number of subjects: 48
Study 14589683 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (both experiments)
Number of subjects: 48
Study 155391 — intervention group
Group type: EXPERIMENTAL
Intervention: Locetamic acid (Cholebrine)
Number of subjects: 503
Study 155391 — intervention group
Group type: COMPARATOR
Intervention: Ipodate sodium (Oragrafin)
Number of subjects: 503
Study 155391 — intervention group
Group type: COMPARATOR
Intervention: Both contrast agents
Number of subjects: 503
Study 31765643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubovisceral muscle tear
Number of subjects: 56
Study 31765643 — intervention group
Group type: COMPARATOR
Intervention: No pubovisceral muscle tear
Number of subjects: 56
Study 30472123 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg IV ibuprofen in 100 mL saline
Number of subjects: 40
Study 30472123 — intervention group
Group type: COMPARATOR
Intervention: 100 mL saline solution
Number of subjects: 40
Study 28283286 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion plus supportive care (4 units of pooled platelets given daily when platelet count was 20,000 per μL or lower)
Number of subjects: 372
Study 28283286 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 372
Study 28283286 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion plus supportive care
Number of subjects: 372
Study 26013860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 291
Study 26013860 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery (COS)
Number of subjects: 291
Study 26013860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 291
Study 23672966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception (HC+)
Number of subjects: 209
Study 21429018 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone PEG tubes
Number of subjects: 60
Study 21429018 — intervention group
Group type: COMPARATOR
Intervention: Latex PEG tubes
Number of subjects: 60
Study 19623149 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol plus ipratropium bromide
Number of subjects: 60
Study 19623149 — intervention group
Group type: COMPARATOR
Intervention: L‐adrenaline
Number of subjects: 60
Study 17316372 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol
Number of subjects: 20
Study 17316372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15212350 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 54
Study 15212350 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin
Number of subjects: 54
Study 15212350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11599649 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-mg weekly enteric-coated fluoxetine
Number of subjects: 501
Study 11599649 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg daily fluoxetine
Number of subjects: 501
Study 11599649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 9144027 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG myeloma proteins
Number of subjects: 118
Study 9144027 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2
Number of subjects: 118
Study 9144027 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 stimulated natural killer cells
Number of subjects: 118
Study 9144027 — intervention group
Group type: COMPARATOR
Intervention: Natural killer cell activity in multiple myeloma patients
Number of subjects: 118
Study 9144027 — intervention group
Group type: COMPARATOR
Intervention: Natural killer cell number
Number of subjects: 118
Study 8194326 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative teaching done on a preadmission basis
Number of subjects: 0
Study 8194326 — intervention group
Group type: COMPARATOR
Intervention: Preoperative teaching done on a postadmission basis
Number of subjects: 0
Study 2831788 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10‐20 mg) with hydrochlorothiazide plus amiloride
Number of subjects: 59
Study 2831788 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (10‐20 mg) with hydrochlorothiazide plus amiloride
Number of subjects: 59
Study 29950166 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational advice intervention to facilitate return to work and usual activities
Number of subjects: 0
Study 27267965 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-taught PE program (2×45 min lessons/week for 4 years)
Number of subjects: 853
Study 27267965 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-taught PE program
Number of subjects: 853
Study 25710802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3883
Study 25710802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study 22099039 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide (500 mg twice a day)
Number of subjects: 92
Study 22099039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 19130636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonperiodized (NP) training program
Number of subjects: 51
Study 19130636 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional periodized linear (PL) training program
Number of subjects: 51
Study 19130636 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned nonlinear periodized (PNL) training program
Number of subjects: 51
Study 17128436 — intervention group
Group type: EXPERIMENTAL
Intervention: Harpagophytum procumbens (Devil's Claw)
Number of subjects: 0
Study 15016559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% ophthalmic solution QD (n=38)
Number of subjects: 115
Study 15016559 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% ophthalmic solution QD (n=38)
Number of subjects: 115
Study 15016559 — intervention group
Group type: COMPARATOR
Intervention: Timolol gel-forming ophthalmic solution 0.5% QD (n=39)
Number of subjects: 115
Study 15016559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost and Latanoprost (both QD)
Number of subjects: 115
Study 12516489 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 1 mg/Kg i.m. 60 minutes before surgery and continuous infusion of 1.5 mg/Kg over 24 hours (DD)
Number of subjects: 90
Study 12516489 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 1 mg/Kg i.m. 60 minutes before surgery and infused saline solution after extubation (DP)
Number of subjects: 90
Study 12516489 — intervention group
Group type: COMPARATOR
Intervention: Placebo before surgery and diclofenac afterwards (PD)
Number of subjects: 90
Study 9690730 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m. plus amoxycillin 1000 mg b.d. plus clarithromycin 500 mg b.d. (O20AC500)
Number of subjects: 274
Study 9690730 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m. plus amoxycillin 1000 mg b.d. plus clarithromycin 1000 mg b.d. (O20AC1000)
Number of subjects: 274
Study 9690730 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole b.d. plus amoxycillin 1000 mg b.d. plus clarithromycin 500 mg b.d. (O40AC500)
Number of subjects: 274
Study 9690730 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole b.d. plus amoxycillin 1000 mg b.d. plus clarithromycin 1000 mg b.d. (O40AC1000)
Number of subjects: 274
Study 7864315 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural administration of alfentanil (1 mg followed by 0.2 mg.h-1 infusion)
Number of subjects: 20
Study 7864315 — intervention group
Group type: COMPARATOR
Intervention: Control group (sodium chloride via sham catheter)
Number of subjects: 20
Study 7864315 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural administration of alfentanil
Number of subjects: 20
Study 7864315 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 2817661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 0.05% combined with hydroxyamphetamine 1%
Number of subjects: 0
Study 2817661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 0.1% combined with hydroxyamphetamine 1%
Number of subjects: 0
Study 2817661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 0.25% combined with hydroxyamphetamine 1%
Number of subjects: 0
Study 2817661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 0.5% combined with hydroxyamphetamine 1%
Number of subjects: 0
Study 1081905 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with 1 chemotherapy agent
Number of subjects: 149
Study 1081905 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with 2 chemotherapy agents
Number of subjects: 149
Study 1081905 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with 3 chemotherapy agents
Number of subjects: 149
Study 1081905 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with 4 chemotherapy agents
Number of subjects: 149
Study 1081905 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with 3 drugs plus supplemental chemotherapy or irradiation (special categories)
Number of subjects: 149
Study 30611756 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA, anode right/cathode left targeting the dorsolateral prefrontal cortex for 20 min)
Number of subjects: 74
Study 30611756 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (only for the first and last minute)
Number of subjects: 74
Study 29423663 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive pulse sensing (RPS)
Number of subjects: 0
Study 29423663 — intervention group
Group type: COMPARATOR
Intervention: Dynamic light scattering (DLS)
Number of subjects: 0
Study 29423663 — intervention group
Group type: COMPARATOR
Intervention: Size-exclusion chromatography with in-line multi-angle light scattering (SEC-MALS)
Number of subjects: 0
Study 29423663 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo formulations spiked with silicone oil
Number of subjects: 0
Study 29423663 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein formulations stressed via freeze-thaw cycling, thermal incubation, and acid treatment
Number of subjects: 0
Study 27150493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (showing the larger historical Heartmate XVE before the HMII)
Number of subjects: 487
Study 27150493 — intervention group
Group type: COMPARATOR
Intervention: Control group (only shown the HMII device)
Number of subjects: 487
Study 24482301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg or 90 mg at week 0, week 4, q12 weeks
Number of subjects: 312
Study 24482301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 312
Study 24482301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 22677045 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ixekizumab (5, 15, 50, or 150 mg)
Number of subjects: 40
Study 22677045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22677045 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ixekizumab
Number of subjects: 40
Study 20016250 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver textiles
Number of subjects: 0
Study 20016250 — intervention group
Group type: COMPARATOR
Intervention: Placebo textiles
Number of subjects: 0
Study 20016250 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-based washing at 60 degrees C
Number of subjects: 0
Study 17322427 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 120
Study 17322427 — intervention group
Group type: COMPARATOR
Intervention: Bipolar hemiarthroplasty
Number of subjects: 120
Study 16364049 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg intravenously infused over 10, 15, 20, or 30 minutes
Number of subjects: 24
Study 16364049 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg intravenously as an injection over 3 minutes
Number of subjects: 24